Oriented attachment of VNAR proteins, via site-selective modification, on PLGA–PEG nanoparticles enhances nanoconjugate performance†
Abstract
Herein we report the construction of a nanoparticle-based drug delivery system which targets a key regulator in tumour angiogenesis. We exploit a Variable New Antigen Receptor (VNAR) domain, conjugated using site-specific chemistry, to direct poly lactic acid-co-glycolic acid–polyethylene glycol (PLGA–PEG) nanoparticles to delta like canonical Notch ligand 4 (DLL4). The importance of site-specific chemistry is demonstrated.